Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Combination Immunotherapy before and after Surgery in Treating Patients with Stage I-II Pancreatic Cancer That Can Be Removed by Surgery

Trial Status: active

This phase I/II trial studies how well combination immunotherapy before and after surgery works in treating patients with stage I-II pancreatic cancer that can be removed by surgery (resectable). Vaccines, such as GVAX pancreatic cancer vaccine, made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab, urelumab, or anti-IL-8 monoclonal antibody BMS-986253 may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial is being done to learn more about how the immune system responds and how the tumor might respond to the treatments given and to evaluate if there is an improvement on current therapy (which includes standard surgery and post-surgery treatment with radiation and chemotherapy) with these study drug combinations when they are given both prior to the surgery and following the surgery.